World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
43229
World Ranking
6240
National Ranking
3330

Research.com Recognitions

  • 2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

William Plunkett is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on chronic lymphocytic leukemia (CLL) and related hematological malignancies within the broader field of medicine. The main fields of study for their work include genetics, immunology, molecular biology, pathology and forensic medicine, and oncology.

Their research topics encompass chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, advanced breast cancer therapies, cancer-related molecular pathways, phagocytosis and immune regulation, and chronic myeloid leukemia treatments.

William Plunkett has contributed to several notable publications. Some recent papers are:

  • "Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia," 2021, published in JAMA Oncology
  • "Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up," 2023, published in Blood
  • "Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations," 2021, published in Leukemia
  • "Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells," 2022, published in Leukemia
  • "The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action," 2021, published in Blood Cancer Journal

Their frequent co-authors include:

  • William G. Wierda
  • Michael J. Keating
  • Philip A. Thompson
  • Varsha Gandhi
  • Nitin Jain

William Plunkett has published primarily in well-established journals in hematology and oncology. The venues where they have the most publications are:

  • Blood
  • Cancer Research
  • Leukemia
  • JAMA Oncology
  • Blood Cancer Journal

In recognition of their contributions to science, William Plunkett was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2012.

Best Publications

  • Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

    Kenneth P. Olive;Michael A. Jacobetz;Christian J. Davidson;Aarthi Gopinathan;Aarthi Gopinathan

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

    Peng Huang;Sherri Chubb;Sherri Chubb;Larry W. Hertel;Gerald B. Grindey

  • Superoxide dismutase as a target for the selective killing of cancer cells

    Peng Huang;Li Feng;Elizabeth A. Oldham;Michael J. Keating

  • Gemcitabine : metabolism, mechanisms of action, and self-potentiation

    W. Plunkett;Peng Huang;Yi-Zheng Xu;V. Heinemann

  • Comparison of the Cellular Pharmacokinetics and Toxicity of 2′,2′-Difluorodeoxycytidine and 1-β-d-Arabinofuranosylcytosine

    Volker Heinemann;Larry W. Hertel;Gerald B. Grindey;William K Plunkett

  • Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

    M. J. Keating;Hagop M Kantarjian;M. Talpaz;J. Redman

  • Inhibition of Mitochondrial Respiration A NOVEL STRATEGY TO ENHANCE DRUG-INDUCED APOPTOSIS IN HUMAN LEUKEMIA CELLS BY A REACTIVE OXYGEN SPECIES-MEDIATED MECHANISM

    Helene Pelicano;Li Feng;Yan Zhou;Jennifer S. Carew

  • Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

    Margaret Tempero;William Plunkett;Veronique Ruiz Van Haperen;John Hainsworth

  • Gemcitabine: preclinical pharmacology and mechanisms of action.

    W. Plunkett;P. Huang;C. E. Searcy;V. Gandhi

  • Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

    Philip A. Thompson;Constantine S. Tam;Susan M. O'Brien;William G. Wierda

  • Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

    V. Heinemann;Yi-Zheng Xu;S. Chubb;A. Sen

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

    Varsha Gandhi;Elihu Estey;Michael J. Keating;William Plunkett

  • TRIM24 links a non-canonical histone signature to breast cancer

    Wen Wei Tsai;Zhanxin Wang;Teresa T. Yiu;Teresa T. Yiu;Kadir C. Akdemir

  • Cellular Elimination of 2′,2′-Difluorodeoxycytidine 5′-Triphosphate: A Mechanism of Self-Potentiation

    Volker Heinemann;Yi-Zheng Xu;Sherri Chubb;Alina Sen

  • Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents.

    Yan Zhou;Elizabeth O. Hileman;William Plunkett;Michael J. Keating

  • Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

    Hagop M Kantarjian;Varsha Gandhi;Jorge Cortes;Srdan Verstovsek

  • Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine

    L. E. Robertson;Sherri Chubb;Raymond E. Meyn;Michael Story

Frequent Co-Authors

Varsha Gandhi
Varsha Gandhi The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Elihu H. Estey
Elihu H. Estey University of Washington
Jorge E. Cortes
Jorge E. Cortes Augusta University
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in healthcare careers beyond traditional medical school, there are several flexible options available. For those coming from non-nursing backgrounds, direct entry msn programs for non-nursing majors offer a pathway to advanced nursing credentials without the need for a prior nursing degree. These programs can accelerate your entry into the field and expand your career possibilities.

If you prefer starting with an entry-level role, pursuing an Associate Degree in Nursing (ADN) offers a more accessible route. Many choose adn programs for their shorter duration and practical focus, providing a solid foundation in nursing skills and quicker workforce entry.

Not all healthcare paths involve patient care. If you're interested in the administrative side, consider accredited medical billing and coding online schools. These programs offer hands-on training and often financial aid to help you start a stable career in healthcare administration.

Lastly, some nursing programs make entry even more accessible. Are you wondering, do I need to take the TEAS test for LPN? Many schools now offer routes that don’t require standardized exams like TEAS or HESI, streamlining the admissions process and helping you start your nursing journey sooner.

Best Scientists Citing William Plunkett

Trending Scientists

Recently Published Articles